Zhuhai Rui-Inno Pharmaceutical Technology Co., Ltd.

The study will evaluate the treatment effect of MDI-1228-mesylate Gel compared with standard of care alone for the complete healing rate at the end of 12 weeks in participants with diabetic foot ulcers (targeted ulcer). In addition, the proportion of subjects whose target ulcer area is reduced by 50% after 12 weeks of treatment.

主要目的： 评估MDI-1228_mesylate凝胶在轻、中度AD受试者中多次局部外用涂抹给药的安全性。 次要目的： 评估MDI-1228_mesylate凝胶在轻、中度AD受试者中多次局部外用涂抹给药的有效性； 评估MDI-1228_mesylate凝胶在轻、中度AD受试者中的PK特征。

The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in healthy adult participants.
Participants will receive either of the following treatment:
* MDI-1228_mesylate Ophthalmic Solution, or
* Placebo**
Researchers will observe any changes in health (if any) in participants receiving the study treatment to evaluate the safety and tolerability*** of the study drug. Researchers will also collect several blood samples from participants to study PK profiles of the drug.
Note:
*PK profiles: how the drug interacts with the body. **placebo: a harmless substance that contains no active agents. ***tolerability: how well you can tolerate the drug.